About BPaL

LIFT-TB focuses on speeding access to pretomanid-based regimens. World Health Organization guidelines allow for the programmatic treatment of most DR-TB with pretomanid-based regimens – either BPaL ( pretomanid +bedaquiline + linezolid), or BPaLM (BPaL + moxifloxacin). TB Alliance has studied the BPaL regimen in multiple clinical trials, including Nix-TB and ZeNix, which enrolled people with XDR-TB as well as treatment-intolerant or non-responsive MDR-TB. BPaL has been approved by 16 regulatory authorities, including the U.S. FDA and European Medicines Agency.

Training of the Trainers: Training Kit

DST & LPA Training Materials

Advocacy Training Materials

Fast Track the Cure

Videos

Videos on the launch, status, and impact of LIFT-TB

Dr. Zaw Myint on Launch of LIFT-TB in Myanmar

Dr. Tauhidul Islam on the Impact of LIFT-TB on the Western Pacific